English

|

|

This site
is mobile
responsive


Centrient Pharmaceuticals widens portfolio via Astral SteriTech acquisition

Centrient Pharmaceuticals widens portfolio via Astral SteriTech acquisition

16 Feb 2021

KUALA LUMPUR, Feb 16 — Centrient Pharmaceuticals (Centrient) recently signed an agreement for Astral SteriTech Private Limited (Astral SteriTech) acquisition.

Astral SteriTech is a leading international manufacturer specialised in sterile antibiotic injectable nished dosage forms.

Based on a statement, Centrient said the acquisition strengthened its position as the global business-to-business industry leader in beta-lactam antibiotics.

It is an important step in Centrient’s journey to become the leading, diversified and fully integrated partner to generics marketers.

The products offered by Astral SteriTech are sterile injectable nished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins.

Being close to Centrient’s core products of beta-lactam antibiotics, the acquired product portfolio provides Centrient a diversication opportunity within the attractive growing niche segment of sterile injectable antibiotics.

The transaction is subject to customary regulatory approvals and closing conditions.

Barclays acted as exclusive nancial adviser, and Sidley Austin LLP and Trilegal as legal advisers to Centrient. J.P. Morgan acted as exclusive nancial adviser and Shardul Amarchand Mangaldas & Co, legal adviser to Astral SteriTech.

Source: Bernama

TwitterLinkedInFacebookWhatsApp
wpChatIcon
X